Mabion S.A.

Warsaw Stock Exchange MAB.WA

Mabion S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD 8.75 M

Mabion S.A. Net Cash Used Provided By Financing Activities is USD 8.75 M for the year ending December 31, 2023, a 314.78% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Mabion S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD -4.07 M, a -114.90% change year over year.
Mabion S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 27.34 M, a 705.95% change year over year.
Mabion S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 3.39 M, a 3.40% change year over year.
Mabion S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 3.28 M, a -88.08% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

Warsaw Stock Exchange: MAB.WA

Mabion S.A.

CEO	Mr. Krzysztof Kaczmarczyk
IPO Date	Aug. 10, 2010
Location	Poland
Headquarters	ul. gen. Mariana Langiewicza 60
Employees	241
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics

Description

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. The company was founded in 2007 and is based in Konstantynów Lódzki, Poland.

Key trends

Past 5 years